Gene · 338413
Papers2,372
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 2,372
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations. | Cancer Discov | 2023 | 37270847 | PubTator, text mining | PubMed |
| A bi-steric mTORC1-selective inhibitor overcomes drug resistance in breast cancer. | Oncogene | 2023 | 37264081 | PubTator, text mining | PubMed |
| Uptake of tumor-derived microparticles induces metabolic reprogramming of macrophages in the early metastatic lung. | Cell Rep | 2023 | 37261951 | PubTator, text mining | PubMed |
| Investigation of variants in genetics and virulence of Porcine Epidemic Diarrhea Virus after serial passage on Vero cells. | J Virol Methods | 2023 | 37244432 | PubTator, text mining | PubMed |
| Specific Features of Focal Cortical Dysplasia in Tuberous Sclerosis Complex. | Curr Issues Mol Biol | 2023 | 37232723 | PubTator, text mining | PubMed |
| A small-molecule PI3Kα activator for cardioprotection and neuroregeneration. | Nature | 2023 | 37225977 | PubTator, text mining | PubMed |
| Covalent inhibitor targets KRasG12C: A new paradigm for drugging the undruggable and challenges ahead. | Genes Dis | 2023 | 37223497 | PubTator, text mining | PubMed |
| Cell surface GRP78: a potential mechanism of therapeutic resistant tumors. | Cancer Cell Int | 2023 | 37221596 | PubTator, text mining | PubMed |
| Advances in the mTOR signaling pathway and its inhibitor rapamycin in epilepsy. | Brain Behav | 2023 | 37221133 | PubTator, text mining | PubMed |
| Mass Cytometry reveals unique phenotypic patterns associated with subclonal diversity and outcomes in multiple myeloma. | Blood Cancer J | 2023 | 37217482 | PubTator, text mining | PubMed |
| Loss of BCAA catabolism enhances Rab1A-mTORC1 signaling activity and promotes tumor proliferation in NSCLC. | Transl Oncol | 2023 | 37216755 | PubTator, text mining | PubMed |
| Prospective phase II trial of the dual mTORC1/2 inhibitor vistusertib for progressive or symptomatic meningiomas in persons with neurofibromatosis 2. | Neurooncol Adv | 2023 | 37215956 | PubTator, text mining | PubMed |
| UBE2C promotes leptomeningeal dissemination and is a therapeutic target in brain metastatic disease. | Neurooncol Adv | 2023 | 37215954 | PubTator, text mining | PubMed |
| G-protein-coupled receptor 141 mediates breast cancer proliferation and metastasis by regulating oncogenic mediators and the p-mTOR/p53 axis. | Oncotarget | 2023 | 37204251 | PubTator, text mining | PubMed |
| Targeting PELP1 oncogenic signaling in TNBC with the small molecule inhibitor SMIP34. | Breast Cancer Res Treat | 2023 | 37199805 | PubTator, text mining | PubMed |
| Salvage of ribose from uridine or RNA supports glycolysis in nutrient-limited conditions. | Nat Metab | 2023 | 37198474 | PubTator, text mining | PubMed |
| Glucose metabolic upregulation via phosphorylation of S6 ribosomal protein affects tumor progression in distal cholangiocarcinoma. | BMC Gastroenterol | 2023 | 37193984 | PubTator, text mining | PubMed |
| An immunosuppressed microenvironment distinguishes lateral ventricle-contacting glioblastomas. | JCI Insight | 2023 | 37192001 | PubTator, text mining | PubMed |
| Combination Treatment Targeting mTOR and MAPK Pathways Has Synergistic Activity in Multiple Myeloma. | Cancers (Basel) | 2023 | 37190302 | PubTator, text mining | PubMed |
| AI-Predicted mTOR Inhibitor Reduces Cancer Cell Proliferation and Extends the Lifespan of C. elegans. | Int J Mol Sci | 2023 | 37175557 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/338413/papers?page=10